Patent application number | Description | Published |
20110189243 | PHARMACEUTICAL FORMULATION FOR LOWERING PULMONARY BLOOD PRESSURE - The invention relates to pharmaceutical formulations for reducing pulmonary blood pressure containing micronised ambrisentan, preferably in the form of an intermediate together with a hydrophilising agent. The invention also relates to methods of preparing pharmaceutical formulations containing micronised ambrisentan. | 08-04-2011 |
20110189279 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions with modified release properties comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and process of preparing such compositions. | 08-04-2011 |
20110300214 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions. | 12-08-2011 |
20110313050 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-22-2011 |
20120009258 | COMPACTED CINACALCET - The invention relates to an intermediate, obtainable by jointly compacting (i) crystalline cinacalcet or a pharmaceutically acceptable salt thereof, with (ii) a hydrophilising agent, and also tablets containing the intermediates of the invention. The invention further relates to cinacalcet tablets with a bimodal pore size distribution and a method of preparing the tablets of the invention. Finally, the invention relates to the use of a pH adjuster for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 01-12-2012 |
20120022087 | AMORPHOUS AMBRISENTAN - The invention relates to amorphous ambrisentan, preferably together with a surface stabiliser in the form of a stable intermediate. The invention further relates to methods of producing stable amorphous ambrisentan and pharmaceutical formulations containing stable amorphous ambrisentan. | 01-26-2012 |
20120122973 | DRY PROCESSING OF RETIGABINE - The invention relates to dry processes for the production of oral dosage forms, especially tablets, containing retigabine and adhesion promoter. In addition, the invention relates to compacted intermediates containing retigabine and an adhesion promoter. Finally, the invention relates to single-dose and multiple-dose containers, preferably sachets and stick-packs, containing the intermediate of the invention. | 05-17-2012 |
20120128773 | DESFESOTERODINE IN THE FORM OF A TARTARIC ACID SALT - The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form. | 05-24-2012 |
20120149727 | PRASUGREL IN NON-CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention relates to prasugrel or a pharmaceutically compatible salt thereof, compositions that contain this active substance and pharmaceutical compositions that contain this active substance or a composition containing this active substance. The present invention further relates to methods for producing the novel compositions. | 06-14-2012 |
20120270949 | MELT-GRANULATED CINACALCET - The invention relates to an intermediate obtainable by the melt-extrusion of (i) cinacalcet or a pharmaceutically acceptable salt thereof with (ii) a matrix former, and oral dosage forms, especially tablets containing the intermediates of the invention. The invention further relates to a method of preparing the tablets of the invention. Finally, the invention relates to the use of a matrix former and a wicking agent for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 10-25-2012 |
20120308652 | ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR - The invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis-B virus infections, containing micronised Entecavir, and processes for preparing it. The invention further relates to intermediates containing micronised entecavir, in which the D50 value for the particle size distribution is less than 50 μm, and processes for preparing them. | 12-06-2012 |
20130035355 | PRASUGREL IN MICRONIZED, CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions. | 02-07-2013 |
20130095177 | METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD - The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form containing fingolimod and accordingly intermediates, granules and oral dosage forms obtainable by that method. | 04-18-2013 |
20130102682 | FINGOLIMOD IN THE FORM OF A SOLID SOLUTION - The invention relates to an intermediate containing fingolimod and matrix material, wherein the fingolimod is present in the matrix material in the form of a solid solution. The invention also relates to granules and pharmaceutical formulations containing fingolimod in the form of a solid solution in matrix material. The subject matter of the invention further relates to methods of preparing a solid solution of fingolimod or of an intermediate, and also granules and pharmaceutical formulations containing fingolimod in the form of a solid solution. | 04-25-2013 |
20130102683 | MELT-GRANULATED FINGOLIMOD - The invention relates to methods including the step of joint melt processing of (i) fingolimod or a pharmaceutically acceptable salt thereof, with (ii) a matrix former into an intermediate, intermediates obtainable in this way, and oral dosage forms, especially tablets, containing the intermediates of the invention. The invention further relates to a method of preparing the dosage forms of the invention, especially tablets. Finally, the invention relates to oral dosage forms for the treatment of multiple sclerosis. | 04-25-2013 |
20130116333 | SOLID TAPENTADOL IN NON-CRYSTALLINE FORM - The invention relates to solid tapentadol in non-crystalline form together with a surface stabiliser in the form of a stable intermediate. In the intermediate of the invention, tapentadol is preferably present in amorphous form or in the form of a solid solution. The invention further relates to methods of producing tapentadol in a solid, non-crystalline form and to pharmaceutical formulations containing solid, non-crystalline tapentadol. | 05-09-2013 |
20130142871 | ORAL DOSAGE FORM OF DEFERASIROX - The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 μm to 120 μm, and also to a method of producing it. | 06-06-2013 |
20130149346 | DABIGATRAN ETEXILATE-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient. | 06-13-2013 |
20130281457 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-mor-pholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarbox-amid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions. | 10-24-2013 |
20130345310 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-26-2013 |
20140319720 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN - The invention relates to pharmaceutical compositions comprising rivaroxaban, suitable for immediate release, and processes of preparing such compositions, preferably by a melt-granulation process or by a specific direct-compression process. | 10-30-2014 |
Patent application number | Description | Published |
20100233102 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS - The invention provides the use of
| 09-16-2010 |
20100292175 | USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION - The present invention primarily relates to the use of specific compounds of formula (I) | 11-18-2010 |
20110076239 | REDUCED-SWEETENER PRODUCTS, FLAVORING MIXTURES FOR SAID REDUCED-SWEETENER PRODUCTS AND PROCESS FOR THE PRODUCTION OF PRODUCTS OF THIS TYPE - A flavoring mixture, comprising
| 03-31-2011 |
20110189108 | USE OF 1-(2,4-DIHYDROXY-PHENYL)-3-(3-HYDROXY-4-METHOXY-PHENYL)-PROPAN-1-ON- E - The invention concerns the use of a
| 08-04-2011 |
20110293538 | USE OF RUBUSOSIDE FOR REDUCING OR SUPPRESSING CERTAIN UNPLEASANT TASTE IMPRESSIONS - The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular | 12-01-2011 |
20120308703 | Cinnamamides as savory flavorings - The use is described of a compound of Formula (I) | 12-06-2012 |
20130078192 | Use of neoflavonoids for flavor modification - The present invention relates primarily to the use of one or a plurality of neoflavonoids of formula (I) and/or one or a plurality of physiologically acceptable salts of one or a plurality of neoflavonoids of formula (I) for flavor modification, in particular for altering or masking a bitter, astringent and/or metallic flavor impression of a bitter, astringent and/or metallic tasting substance and a corresponding method of flavor modification. The present invention further relates to certain mixtures and certain preparations fit for consumption containing one or a plurality of neoflavonoids of formula (I) and/or one or a plurality of physiologically acceptable salts of one or a plurality of neoflavonoids of formula (I). | 03-28-2013 |
20130084252 | Use of certain neoflavonoids for intensifying and/or producing a sensory impression of sweetness - The present invention primarily relates to the use of one or a plurality of neoflavonoids of formula (I) and/or one or a plurality of physiologically acceptable salts of one or a plurality of neoflavonoids of formula (I) for producing a sensory impression of sweetness (i.e. an impression of sweetness) in an orally consumable preparation or for intensifying the sensory impression of sweetness of an orally consumable preparation comprising at least one further sweet-tasting and/or sweet-smelling substance. The present invention further relates to certain semifinished products and certain orally consumable preparations containing one or a plurality of neoflavonoids of formula (I) and/or one or a plurality of physiologically acceptable salts of one or a plurality of neoflavonoids of formula (I). Finally the invention also relates to a method of producing an orally consumable preparation and a method of producing and/or intensifying a sensory impression of sweetness in/of an orally consumable preparation. | 04-04-2013 |
20140287122 | USE OF RUBUSOSIDE FOR REDUCING OR SUPPRESSING CERTAIN UNPLEASANT TASTE IMPRESSIONS - The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular | 09-25-2014 |